Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2007-5-18
pubmed:abstractText
Cinnamaldehyde derivatives isolated from Cinnamomum cassia have been widely used for treating dyspepsia, gastritis, and inflammatory disease as well as cancer. To investigate the anti-tumor activities of several cinnamaldehyde derivatives, we compared the inhibitory effect of cinnamaldehyde derivatives on cell growth and AP-1 transcriptional activity in SW620 human colon cancer cells since AP-1 is a transcriptional factor implicated to control cancer cell growth. Among the derivatives, 2'-hydroxycinnamaldehyde (HCA) most significantly inhibited cancer cell growth and AP-1 transcriptional activity in a dose-dependent manner with an IC50 value of 12.5 and 9 microg/ml, respectively. In further studies on the mechanism, we found that consistent with the inhibitory effect on cell growth, HCA dose-dependently (0-20 microg/ml) inhibited DNA binding activity of AP-1 accompanied with down regulation of c-Jun and c-Fos expressions. HCA also induced apoptotic cell death as well as expression of the apoptosis-regulating gene caspase-3, but inhibited the anti-apoptosis regulating gene bcl-2 in a dose-dependent manner. These results suggested that HCA has the most potent inhibitory effect against human colon cancer cell growth, and AP-1 may be an important target of HCA.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1347-8613
pubmed:author
pubmed:issnType
Print
pubmed:volume
104
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
19-28
pubmed:dateRevised
2007-10-10
pubmed:meshHeading
pubmed-meshheading:17510524-Acrolein, pubmed-meshheading:17510524-Apoptosis, pubmed-meshheading:17510524-Blotting, Western, pubmed-meshheading:17510524-Cell Line, Tumor, pubmed-meshheading:17510524-Cell Proliferation, pubmed-meshheading:17510524-Cell Survival, pubmed-meshheading:17510524-Cinnamates, pubmed-meshheading:17510524-DNA-Binding Proteins, pubmed-meshheading:17510524-Dose-Response Relationship, Drug, pubmed-meshheading:17510524-Electrophoretic Mobility Shift Assay, pubmed-meshheading:17510524-Growth Inhibitors, pubmed-meshheading:17510524-Humans, pubmed-meshheading:17510524-In Situ Nick-End Labeling, pubmed-meshheading:17510524-Inhibitory Concentration 50, pubmed-meshheading:17510524-Luciferases, pubmed-meshheading:17510524-Molecular Structure, pubmed-meshheading:17510524-Oligonucleotides, pubmed-meshheading:17510524-Protein Binding, pubmed-meshheading:17510524-Proto-Oncogene Proteins c-fos, pubmed-meshheading:17510524-Proto-Oncogene Proteins c-jun, pubmed-meshheading:17510524-Structure-Activity Relationship, pubmed-meshheading:17510524-Transcription Factor AP-1, pubmed-meshheading:17510524-Transfection
pubmed:year
2007
pubmed:articleTitle
2-hydroxycinnamaldehyde inhibits SW620 colon cancer cell growth through AP-1 inactivation.
pubmed:affiliation
College of Pharmacy, Chungbuk National University, Korea.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't